First Multiplatform Study Compares Robotic Systems for Colon Cancer Surgery

What Happened

A recent prospective study evaluated the performance of three robotic surgical systems—Da Vinci Xi, Hugo™ RAS, and Versius®—in colon cancer resections. This research represents an initial comparison of these platforms, two of which are newer to the European market.

The study involved 45 adult patients undergoing robotic colon surgery, with 15 procedures performed on each platform by two experienced colorectal surgeons. Researchers focused on primary outcomes such as conversion rates to traditional laparoscopic or open surgery, and intra-operative complications.

Results indicated no conversions in the Da Vinci group, while Hugo™ RAS recorded two and Versius® three conversions to laparoscopy. One instrument malfunction occurred with Hugo™ RAS, and each system had one reported surgical complication. Importantly, no significant variations were found in patient post-operative recovery or oncological outcomes across the three platforms.

The Versius® system required more frequent use of supplementary laparoscopic energy devices during its cases. Overall, the findings suggest that all three robotic platforms are functional for colorectal surgery when operated by proficient surgeons.

The Core Points

First prospective study comparing Da Vinci, Hugo RAS, and Versius robotic systems for colon surgery.
45 patients underwent procedures, 15 on each robotic platform.
Da Vinci system showed no conversions to traditional surgery.
Hugo RAS and Versius recorded some conversions to laparoscopy.
No significant differences in post-operative recovery or oncological outcomes were observed.
All three robotic platforms are considered feasible for colorectal surgery by expert surgeons.

Context in 60 Seconds

The field of minimally invasive surgery continues to expand, with robot-assisted procedures gaining traction due to their potential technical benefits. While the Da Vinci system has long been a primary option, new platforms like Hugo™ RAS and Versius® are emerging, increasing the choices available to surgical teams. This trend highlights a growing demand for advanced tools that can improve surgical precision and patient outcomes.

As more robotic systems become available, comparative studies are critical for understanding their respective performances, safety profiles, and cost-effectiveness. This initial multiplatform study contributes to the ongoing evaluation of these technologies, informing surgeons and healthcare providers as they consider adopting or upgrading robotic surgical capabilities.

Bottom Line

This initial comparative study indicates all three robotic systems—Da Vinci, Hugo, and Versius—are viable for colon cancer surgery when skilled surgeons perform the procedures, though minor differences in conversion rates were observed. Further extensive trials are necessary to confirm long-term recovery and oncological effectiveness.

Loading briefing details...

First Multiplatform Study Compares Robotic Systems for Colon Cancer Surgery

What Happened

The Core Points

First prospective study comparing Da Vinci, Hugo RAS, and Versius robotic systems for colon surgery.
45 patients underwent procedures, 15 on each robotic platform.
Da Vinci system showed no conversions to traditional surgery.
Hugo RAS and Versius recorded some conversions to laparoscopy.
No significant differences in post-operative recovery or oncological outcomes were observed.
All three robotic platforms are considered feasible for colorectal surgery by expert surgeons.